WO2006074046A2 - Process for preparing 2-methyl-1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine - Google Patents

Process for preparing 2-methyl-1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine Download PDF

Info

Publication number
WO2006074046A2
WO2006074046A2 PCT/US2005/047375 US2005047375W WO2006074046A2 WO 2006074046 A2 WO2006074046 A2 WO 2006074046A2 US 2005047375 W US2005047375 W US 2005047375W WO 2006074046 A2 WO2006074046 A2 WO 2006074046A2
Authority
WO
WIPO (PCT)
Prior art keywords
methylpropyl
naphthyridine
nitro
mixture
naphthyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/047375
Other languages
English (en)
French (fr)
Other versions
WO2006074046A3 (en
Inventor
Hugues Martin
David Ach
Clement Toussaint
Fabrice Dubois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda AB
3M Innovative Properties Co
Graceway Pharmaceuticals LLC
Original Assignee
Meda AB
3M Innovative Properties Co
Graceway Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11/794,584 priority Critical patent/US8436176B2/en
Priority to MX2007008131A priority patent/MX2007008131A/es
Priority to JP2007549617A priority patent/JP2008526758A/ja
Priority to AT05855868T priority patent/ATE510838T1/de
Priority to PL05855868T priority patent/PL1833827T3/pl
Priority to AU2005322844A priority patent/AU2005322844A1/en
Priority to EP05855868A priority patent/EP1833827B9/en
Priority to BRPI0519797-0A priority patent/BRPI0519797A/pt
Priority to CA002592957A priority patent/CA2592957A1/en
Priority to DK05855868.5T priority patent/DK1833827T3/da
Application filed by Meda AB, 3M Innovative Properties Co, Graceway Pharmaceuticals LLC filed Critical Meda AB
Publication of WO2006074046A2 publication Critical patent/WO2006074046A2/en
Priority to IL184310A priority patent/IL184310A/en
Anticipated expiration legal-status Critical
Publication of WO2006074046A3 publication Critical patent/WO2006074046A3/en
Priority to NO20076651A priority patent/NO339859B1/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the compound 2-methyl- 1 -(2-methylpropyl)- 1 H-imidazo [4,5 -c] [ 1 ,5]naphthyridin- 4-amine has been found to be a useful immune response modifier (IRM) due to its ability to induce cytokine biosynthesis.
  • IRM immune response modifier
  • manufacturing pharmaceutical products can present many unforeseen challenges and new methods of preparation are needed.
  • the invention provides a method for preparing 2-methyl- 1 -(2- methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine.
  • the method includes: providing 2-methyl-l-(2-methylpropyl)-5-oxido-lH-imidazo[4,5-c][l,5]naphthyridine in a carrier that includes a lower alcohol; combining the 2-methyl-l-(2-methylpropyl)-5-oxido- lH-imidazo[4,5-c][l,5]naphthyridine in the carrier with an ammonia- or ammonium- containing reagent and an arylsulfonyl halide to form a mixture; allowing the components of the mixture to react for a period of time sufficient to form 2-methyl- l-(2-methylpropyl)- lH-imidazo[4,5-c][l,5]naphthyridin-4-amine.
  • the method also includes combining the mixture with an aqueous base.
  • providing 2-methyl-l-(2-methylpropyl)-5-oxido-lH-imidazo[4,5- c][l,5]naphthyridine includes: providing 2-methyl-l-(2-methylpropyl)-lH-imidazo[4,5- c][l,5]naphthyridine (referred to above) in a carrier that includes a non-chlorinated solvent at a temperature of 25 °C to 70 °C; combining the 2-methyl- 1 -(2-methylpropyl)- IH- imidazo[4,5-c][l,5]naphthyridine in the carrier with an oxidizing agent to form a mixture and maintaining the mixture at a temperature of 25 °C to 70 °C for a period of time sufficient to form 2-methyl-l-(2-methylpropyl)-5-oxido-l//-imidazo[4,5- c][l,5]naphthyridine; and isolating at
  • providing 2-methyl- 1 -(2-methylpropyl)- li/-imidazo [4,5 - c][l,5]naphthyridine includes: providing N 4 -(2- methylpropyl)[l,5]naphthyridine-3,4-diamine in a carrier that includes a non-chlorinated solvent at a temperature of 18 °C to 30 0 C; combining the N*-(2- methylpropyl)[l,5]naphthyridine-3,4-diamine in the carrier with an organic acid to form a mixture; combining the mixture that includes the iV 4 -(2-methylpropyl)[l,5]naphthyridine- 3,4-diamine and organic acid with a trialkyl orthoacetate at a temperature of 70 0 C to 100 0 C; and maintaining the temperature at 70 0 C to 100 °C for a period of time sufficient to form 2-
  • providing ⁇ -P-methylpropylXl ,5]naphthyridine-3,4-diamine includes: providing N 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine in a carrier that includes a non-chlorinated solvent; combining the iV 4 -(2-methylpropyl)-3- nitro[l,5]naphthyridin-4-amine in the carrier with a hydrogenation catalyst to form a mixture; subjecting the mixture that includes the N 4 -(2-methylpropyl)-3- nitro[l ,5]naphthyridin-4-amine and the hydrogenation catalyst to a hydrogen atmosphere under conditions effective to form ⁇ -(2-methylpropyl)[l,5]naphthyridine-3,4-diamine; and removing at least a portion of the hydrogenation catalyst from the N 4 - ⁇ - methylpropyl)[l,
  • providing A/ 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine includes: providing 4-chloro-3-nitro[l,5]naphthyridine in a carrier that includes a water-miscible organic liquid; combining the 4-chloro-3- nitro[l,5]naphthyridine in the carrier with isobutylamine under conditions effective to form a mixture that includes the N 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine; combining the mixture that includes the iV 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4- amine with water to form solid 7V 4 -(2-methylpropyl)-3-nitro[l ,5]naphthyridin-4-amine; and separating at least a portion of solid N 4 -(2-methylpropyl) in a carrier that includes
  • providing 4-chloro-3-nitro[l,5]naphthyridine includes: providing 3-nitro[l,5]naphthyridin-4-ol in a carrier that includes N 1 N- dimethylformamide; combining the 3-nitro[l,5]naphthyridin-4-ol in the carrier with phosphorous oxychloride under conditions effective to form 4-chloro-3- nitro[l ,5]naphthyridine; combining the mixture that includes the 4-chloro-3- nitro[l,5]naphthyridine with water under conditions effective to form solid 4-chloro-3- nitro[l,5]naphthyridine; and separating at least a portion of the solid 4-chloro-3- nitro[l,5]naphthyridine from at least a portion of the mixture that includes the water.
  • providing 2-methyl-l-(2-methylpropyl)-5-oxido-l/z r - imidazo[4,5-c][l,5]naphthyridine includes: providing 3- nitro[l,5]naphthyridin-4-ol in a carrier including iV.N-dimethylformamide; combining the 3-nitro[l,5]naphthyridin-4-ol in the carrier with phosphorous oxychloride under conditions effective to form 4-chloro-3-nitro[l,5]naphthyridine; combining the mixture that includes the 4-chloro-3-nitro[l,5]naphthyridine with water under conditions effective to form solid 4-chloro-3-nitro[l,5]naphthyridine; separating at least a portion of the solid 4-chloro-3.- nitro[l,5]naphthyridine from at least a portion of the mixture that
  • the invention provides a method for making 7V 4 -(2-methylpropyl)-3- nitro[l,5]naphthyridin-4-amine.
  • the method includes: providing 3- nitro[l,5]naphthyridin-4-ol in a carrier including ⁇ N-dimethylformamide; combining the 3-nitro[l,5]naphthyridin-4-ol in the carrier with phosphorous oxychloride under conditions effective to form 4-chloro-3-nitro[l,5]naphthyridine; combining the mixture that includes the 4-chloro-3-nitro[l,5]naphthyridine with water under conditions effective to form solid 4-chloro-3-nitro[l,5]naphthyridine; separating at least a portion of the solid 4-chloro-3- nitro[l ,5]naphthyridine from at least a portion of the mixture that includes the water; combining the separated solid 4-chlor
  • the invention provides a method for making 2-methyl- 1 -(2- methylpropyl)-5-oxido-l//-imidazo[4,5-c][l,5]naphthyridine.
  • the method includes: providing N 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine in a carrier including toluene; combining the iV 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine in the carrier with a hydrogenation catalyst and isopropanol to form a mixture; subjecting the mixture that includes the N 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine and the hydrogenation catalyst to a hydrogen atmosphere under conditions effective to form N 4 -(2- methylpropyl)[l,5]naphthyridine-3,4-diamine; removing at least a portion of the hydrogen
  • providing iV 4 -(2-methylpropyl)-3- nitro[l,5]naphthyridin-4-amine includes: providing 3- nitro[l,5]naphthyridin-4-ol in a carrier including Af N-dimethylformamide; combining the 3-nitro[l,5]naphthyridin-4-ol in the carrier with phosphorous oxychloride under conditions effective to form 4-chloro-3-nitro[l,5]naphthyridine; combining the mixture that includes the 4-chloro-3-nitro[l ,5]naphthyridine with water under conditions effective to form solid 4-chloro-3-nitro[l,5]naphthyridine; separating at least a portion of the solid 4-chloro-3- nitro[l,5]naphthyridine from at least a portion of the mixture that includes the water; combining the separated solid 4-chloro-3
  • these groups have a total of up to 10 carbon atoms, up to 8 carbon atoms, up to 6 carbon atoms, or up to 4 carbon atoms.
  • Cyclic groups can be monocyclic or poly cyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopropylmethyl, cyclopentyl, and cyclohexyl.
  • aryl in reference to "arylsulfonyl halide” includes carbocyclic aromatic rings or ring systems that may be unsubstituted or substituted. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl.
  • substituents that may be present on the aryl group include alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, cyano, aryl, aryloxy, and arylalkyleneoxy.
  • a "lower alcohol” i.e., a Ci -4 alcohol
  • Ci -4 alcohol is understood to be a straight chain or branched chain alcohol containing one to four carbon atoms. Examples include, methanol, ethanol, n-propanol, isopropanol, r ⁇ -butanol, .yeobutanol, and tert-butanol.
  • steps (1) and (2) can be carried out as discussed herein, and various other methods can be used to convert the product of step 2 (iV 4 -(2-methylpropyl)-3- nitro[l,5]naphthyridin-4-amine) into the product of step 5 (2-methyl-l-(2-methylpropyl)- 5-oxido-l/i-imidazo[4,5-c][l,5]naphthyridine), which can then be used in the process of step (6) as described herein. Any one of steps (1) through (5) can also be carried out according to the methods described in U.S. Patent No. 6,194,425 (Gerster, et al).
  • the present invention provides a method for preparing 4-chloro-3-nitro[l,5]naphthyridine.
  • the method includes: providing 3-nitro[l,5]naphthyridin-4-ol in a carrier that includes ⁇ iV-dimethylformamide (DMF); combining the 3-nitro[l ,5]naphthyridin-4-ol in the carrier with phosphorous oxychloride under conditions effective to form 4-chloro-3-nitro[l,5]naphthyridine; combining the mixture that includes the 4-chloro-3-nitro[l,5]naphthyridine with water under conditions effective to form solid 4-chloro-3-nitro[l,5]naphthyridine; and separating at least a portion of the solid 4-chloro-3-nitro[l,5]naphthyridine from at least a portion of the mixture that includes the water.
  • DMF ⁇ iV-dimethylformamide
  • this method is carried out under nitrogen, although other inert gases can be used (e.g., argon) if desired.
  • inert gases e.g., argon
  • the DMF not only functions as a reaction solvent, but it typically reacts first with phosphorus oxychloride to form an active intermediate.
  • combining the 3-nitro[l,5]naphthyridin-4-ol with phosphorous oxychloride involves using at least one equivalent of phosphorous oxychloride.
  • the phosphorous oxychloride is added to the 3-nitro- [l,5]naphthyridin-4-ol. Preferably, this addition occurs relatively slowly (e.g., over a period of at least 30 minutes).
  • the conditions effective to form 4-chloro-3- nitro[l,5]naphthyridine include a temperature of at least 15 °C. In some embodiments, the temperature is at least 20 0 C. In some embodiments, the conditions effective to form 4- chloro-3-nitro[l,5]naphthyridine include a temperature of no greater than 35 °C. In some embodiments, the temperature is no greater than 20 °C. In some embodiments, these conditions include a time period of at least one hour, and, if desired, up to 21 hours.
  • This method then involves forming solid (i.e., precipitating) 4-chloro-3- nitro[l,5]naphthyridine using water.
  • the mixture that includes the 4-chloro-3- nitro[l,5]naphthyridine is added to the water.
  • the conditions that allow for the formation of the solid include cooling the mixture that includes the water to a temperature of less than 20 °C. In certain embodiments, the temperature is less than 15 0 C. Generally, the water is pre-cooled, and during the addition, the mixture is maintained at a temperature of less than 20 0 C. In certain embodiments, the temperature is at least 5 0 C.
  • separating at least a portion of the solid 4-chloro-3- nitro[l,5]naphthyridine involves filtering the solid 4-chloro-3-nitro[l,5]naphthyridine from the mixture that includes the water.
  • a precipitate there are many other ways to separate the solid (i.e., a precipitate) from the mixture, such as decanting and centrifugation. After separation, the precipitate may optionally be washed with water to remove impurities.
  • separating at least a portion of the solid 4-chloro-3- nitro[l,5]naphthyridine occurs less than 30 minutes after combining the mixture that includes the 4-chloro-3-nitro[l,5]naphthyridine with water.
  • the solid 4-chloro-3-nitro[l,5]naphthyridine is used in the next step (step 2 of Scheme I, e.g., combined with isobutylamine, as discussed in greater detail below) within less than 4 hours of its preparation.
  • the present invention provides a method for preparing N 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine.
  • This method includes: providing 4-chloro-3-nitro[l,5]naphthyridine in a carrier that includes a water-miscible organic liquid; combining the 4-chloro-3-nitro[l,5]naphthyridine in the carrier with isobutylamine under conditions effective to form a mixture including N 4 -(2- methylpropyl)-3-nitro[l,5]naphthyridin-4-amine; combining the mixture that includes the N 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine with water; and separating at least a portion of solid N 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine from at least a portion of the mixture
  • the water-miscible organic liquid is selected from the group consisting of tetrahydrofuran, dichloromethane, acetonitrile, and mixtures thereof. In some embodiments, the water-miscible organic liquid is tetrahydrofuran.
  • the 4-chloro-3-nitro[l,5]naphthyridine is combined with at least two equivalents of isobutylamine. This provides one equivalent used to scavenge the HCl formed during the reaction and another one to react with 4-chloro-3- nitro[l,5]naphthyridine. In some embodiments, at least 2.05 equivalents are used, and in some embodiments up to 2.4 equivalents are used if desired.
  • the isobutylamine is added to the 4-chloro-3-nitro[l,5]naphthyridine in the water-miscible organic liquid. This addition preferably occurs relatively slowly (e.g., over a period of at least 30 minutes).
  • the conditions effective to form N 4 -(2-methylpropyl)-3- nitro[l,5]naphthyridin-4-amine include a temperature of at least 15 0 C. In some embodiments, the temperature is at least 20 °C. In some embodiments, the temperature is at most 30 0 C. In some embodiments, this temperature is maintained for at least 30 minutes, and in some embodiments for at least 3 hours.
  • Water is then typically used to precipitate solid N 4 -(2-methylpropyl)-3- nitro[l,5]naphthyridin-4-amine, although solid 7V 4 -(2-methylpropyl)-3- nitro[l,5]naphthyridin-4-amine can form before the reaction mixture is added to water or water is added to the reaction mixture.
  • separating at least a portion of the solid N 4 -(2- methylpropyl)-3-nitro[l,5]naphthyridin-4-amine involves filtering the solid N 4 -(2- methylpropyl)-3-nitro[l,5]naphthyridin-4-amine.
  • the method can further include washing and drying this solid if desired.
  • the precipitate may optionally be washed with water to remove impurities.
  • there are many ways to dry the precipitate This includes, for example, using elevated temperatures, desiccation, reduced pressure, using a dry (e.g., nitrogen) atmosphere, and the like.
  • drying the precipitate occurs at a temperature range of 45 0 C to 55 0 C while under at least a partial vacuum.
  • at least partially drying the precipitate occurs under at least a partial vacuum.
  • the present invention provides a method for preparing N 4 -(2-methylpropyl)[l,5]naphthyridine-3,4-diamine.
  • This method involves: providing N 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine in a carrier that includes a non-chlorinated solvent; combining the N 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4- amine in the carrier with a hydrogenation catalyst to form a mixture; subjecting the mixture that includes the ⁇ / 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine and the hydrogenation catalyst to a hydrogen atmosphere under conditions effective to form ⁇ / 4 -(2- methylpropyl)[l,5]naphthyridine-3,4-diamine; and removing at least a portion of the hydrogenation catalyst from the
  • the non-chlorinated solvent is selected from the group consisting of toluene, butyl acetate, ethyl acetate, and combinations thereof. In some embodiments, the non-chlorinated solvent is toluene.
  • combining the N 4 -(2-methylpropyl)-3- nitro[l ,5]naphthyridin-4-amine in the carrier with a hydrogenation catalyst includes combining the N 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine in the carrier with a hydrogenation catalyst and isopropanol to form a mixture.
  • the hydrogenation catalyst and isopropanol can be added simultaneously or sequentially in either order.
  • the hydrogenation catalyst includes platinum, although it is believed that palladium may also work.
  • the hydrogenation catalyst is platinum on carbon.
  • a preferred load level of platinum on carbon is at least 1.5 weight percent of platinum metal on carbon. Typical load levels of platinum on carbon at up to 10 weight percent of platinum metal on carbon.
  • the conditions effective to form N 4 -(2- methylpropyl)[l,5]naphthyridine-3,4-diamine include a temperature of at least 15 0 C. In some embodiments, this temperature is at least 18 °C. In some embodiments, the conditions effective to form N 4 -(2-methylpropyl)[l,5]naphthyridine-3,4-diamine include a temperature of no greater than 30 0 C. In some embodiments, this temperature is no greater than 25 0 C.
  • the conditions effective to form N 4 -(2- methylpropyl)[l,5]naphthyridine-3,4-diamine include a hydrogen pressure of 1 x 10 5 Pa to 3 x 10 5 Pa (i.e., 1 bar to 3 bars), although higher pressures can be used. It is desirable to use the lowest hydrogen pressure possible to avoid equipment concerns.
  • the conditions effective to form I ⁇ -(2- methylpropyl)[l,5]naphthyridine-3,4-diamine include a time period of at least 3 hours. Shorter reaction times may be possible, however, this can depend on the hydrogenation vessel (stirrer) and on the operating conditions (e.g., dilution, quantity of catalyst). Longer reaction times (e.g., up to 22 hours) are also possible.
  • the method involves subsequently removing at least a portion of the isopropanol from the mixture of N 4 -(2-methylpropyl)[l,5]naphthyridine-3,4- diamine in a carrier that includes toluene and isopropanol.
  • the hydrogenation catalyst is removed and, in some embodiments, the
  • N 4 -(2-methylpropyl)[l,5]naphthyridine-3,4-diamine is used in the next step (step 4 of Scheme I, e.g., combined with an organic acid, as discussed in greater detail below) without being isolated.
  • the present invention provides a method for preparing 2-methyl-l-(2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridine.
  • the method includes: providing N 4 -(2-methylpropyl)[l,5]naphthyridine-3,4-diamine in a carrier including a non-chlorinated solvent at a temperature of at least 18 0 C (and typically no more than 30 0 C); combining the N 4 -(2-methylpropyl)[l,5]naphthyridine-3,4-diamine in the carrier with an organic acid to form a mixture; combining the mixture that includes the N 4 -(2-methylpropyl)[l 5 5]naphthyridine-3,4-diamine and organic acid with a trialkyl orthoacetate at a temperature of at least 70 0 C (and typically no more than 100 0 C, and preferably no more than 90
  • the non-chlorinated solvent is selected from the group consisting of toluene, butyl acetate, ethyl acetate, and combinations thereof. In some embodiments, the non-chlorinated solvent is toluene.
  • the organic acid is selected from the group consisting ofp- toluenesulfonic acid, trifluoroacetic acid, ethanesulfonic acid, and mixtures thereof. In some embodiments, the organic acid is p-toluenesulfonic acid.
  • At least 0.02 equivalent of an organic acid is used. In some embodiments, up to 0.08 equivalent of an organic acid is used.
  • the organic acid is added to the ⁇ /4 -(2-methylpropyl)[l,5]naphthyridine- 3,4-diamine in a carrier including a non-chlorinated solvent (e.g., the material from step (3) of Scheme I).
  • a carrier including a non-chlorinated solvent e.g., the material from step (3) of Scheme I.
  • the trialkyl orthoacetate can be triethyl orthoacetate or trimethyl orthoacetate. In some embodiments, the trialkyl orthoacetate is triethyl orthoacetate. In some embodiments, at least one equivalent of the trialkyl orthoacetate is used.
  • At least 1.1 equivalents of a trialkyl orthoacetate are used. In some embodiments, up to 1.4 equivalents of a trialkyl orthoacetate are used.
  • combining the mixture that includes the iV 4 -(2- methylpropyl)[l,5]naphthyridine-3,4-diamine and organic acid with a trialkyl orthoacetate occurs by heating the mixture of N 4 -(2-methylpropyl)[l,5]naphthyridine-3,4-diamine and organic acid to a temperature of 70 °C to 100 0 C, followed by adding the trialkyl orthoacetate to the mixture. Generally, this addition occurs relatively slowly (e.g., over a period of at least 30 minutes).
  • maintaining the temperature at 70 0 C to 100 0 C for a period time sufficient to form 2-methyl-l-(2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridine involves maintaining the temperature at 70 0 C to 100 0 C for at least 30 minutes. In some embodiments, the temperature is maintained at 70 0 C to 100 °C for at least 2 hours. In some embodiments, the temperature is maintained at 70 0 C to 100 °C for up to 6 hours.
  • the method further includes a step of cooling the mixture that includes 2-methyl-l-(2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridine to a temperature of no greater than 70 °C, preferably no greater than 55 0 C. Typically, this temperature is at least 25 0 C, preferably at least 40 °C, and more preferably at least 45 °C.
  • the 2-methyl-l-(2-methylpropyl)-lH-imidazo[4,5- c][l,5]naphthyridine is used in the next step of the process (step 5 of Scheme I, e.g., and combined with an oxidizing agent) without being isolated.
  • the present invention provides a method for preparing 2-methyl-l-(2-methylpropyl)-5-oxido-lH-imidazo[4,5-c][l,5]naphthyridine.
  • This method includes: providing 2-methyl-l-(2-methylpropyl)-l//-imidazo[4,5- c][l,5]naphthyridine in a carrier that includes a non-chlorinated solvent at a temperature of at least 25 °C (and typically up to 70 0 C); combining the 2-methyl-l-(2-methylpropyl)-lH- imidazo[4,5-c] [1 ,5]naphthyridine in the carrier with an oxidizing agent to form a mixture and maintaining the mixture at a temperature of at least 25 0 C (and typically up to 70 0 C) for a period of time sufficient to form 2-methyl-l-(2-methylpropyl)-5-oxido-li : /- imi
  • the non-chlorinated solvent is selected from the group consisting of toluene, butyl acetate, ethyl acetate, and combinations thereof. In some embodiments, the non-chlorinated solvent is toluene.
  • the temperature of the 2-methyl-l-(2-methylpropyl)-lH- imidazo[4,5-c][l,5]naphthyridine in a carrier that includes a non-chlorinated solvent is a temperature of at least 40 °C, and in other embodiments, the temperature is at least 45 °C. In some embodiments, the temperature of the 2-methyl-l-(2-methylpropyl)-lH- imidazo[4,5-c][l,5]naphthyridine in a carrier that includes a non-chlorinated solvent is a temperature of at most 55 0 C.
  • the oxidizing agent includes peracetic acid, although other similar oxidizing agents could be used if desired. In some embodiments, at least one equivalent of oxidizing agent (preferably peracetic acid) is used. In some embodiments, at least 1.2 equivalents of oxidizing agent are used.
  • the oxidizing agent is added to the 2-methyl-l-(2-methylpropyl)-lH- imidazo[4,5-c][l,5]naphthyridine.
  • the oxidizing agent addition is generally exothermic. With peracetic acid, there is a theoretical adiabatic temperature rise of 29 0 C if all the acid is added at once. Therefore, this addition is preferably carried out in a controlled manner to maintain the reaction mixture in the desired temperature range. Preferably, the addition is carried out over at least 2 hours. Preferably, subsequent stirring is carried out for a period of at least 4 hours.
  • the mixture of 2-methyl-l-(2-methylpropyl)-lH- imidazo[4,5-c][l,5]naphthyridine in the carrier with an oxidizing agent is maintained at a temperature of at least 40 0 C. In some embodiments, the mixture of 2 -methyl- 1 -(2- methylpropyl)-l/f-imidazo[4,5-c][l,5]naphthyridine in the carrier with an oxidizing agent is maintained at a temperature of at least 45 °C.
  • the mixture of 2- methyl-l-(2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridine in the carrier with an oxidizing agent is maintained at a temperature of at most 55 °C.
  • the period of time sufficient to form 2 -methyl- 1 -(2- methylpropyl)-5-oxido-l/J-imidazo[4,5-c][l,5]naphthyridine includes a period of time sufficient to react at least 80% of the 2-methyl-l-(2-methylpropyl)-li ⁇ -imidazo[4,5- c][l,5]naphthyridine.
  • the period of time sufficient to react at least 80% of the 2-methyl-l-(2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridine is at least 5 hours (and often up to 7 hours).
  • isolating the 2-methyl-l-(2-methylpropyl)-5-oxido-lH- imidazo[4,5-c][l,5]naphthyridine includes: combining the mixture that includes the 2- methyl-l-(2-methylpropyl)-5-oxido-lH-imidazo[4,5-c][l,5]naphthyridine with an aqueous solution of a reducing agent followed by an aqueous base; cooling the mixture to form solid 2-methyl-l -(2-methylpropyl)-5-oxido-lH-imidazo[4,5-c][l ,5]naphthyridine; and separating at least a portion of the solid 2-methyl-l-(2-methylpropyl)-5-oxido-lH- imidazo[4,5-c][l,5]naphthyridine from at least a portion of the mixture.
  • the reducing agent is selected from the group consisting of sodium metabisulfrte, sodium sulfite, ferrous sulfate, and combinations thereof. In some embodiments, the reducing agent is sodium metabisulfite.
  • an aqueous solution of at least 0.1 equivalent sodium metabisulfite is used. In some embodiments, an aqueous solution of at least 0.3 equivalent sodium metabisulfite is used.
  • a sufficient amount of aqueous base is used to adjust the mixture to a pH of greater than 10.
  • 4 to 4.5 equivalents of sodium hydroxide are used to reach the targeted pH.
  • six to ten milliliters of water per gram of 2-methyl-l-(2- methylpropyl)-5-oxido-lH-imidazo[4,5-c][l,5]naphthyridine are combined with a mixture of eight to twelve milliliters of toluene per gram of 2-methyl-l-(2-methylpropyl)-5-oxido- lH-imidazo[4,5-c][l,5]naphthyridine.
  • the volume ratio of water to toluene is 0.8:1.
  • the cooling step involves cooling to a temperature of no greater than 20 °C. In some embodiments, the cooling step involves cooling to a temperature of no greater than 7 0 C. In some embodiments, the cooling step involves cooling to a temperature of at least 0 °C. In some embodiments, the cooling step involves cooling to a temperature of at least 3 0 C.
  • separating at least a portion of the solid 2-methyl-l-(2- methylpropyl)-5-oxido-lH-imidazo[4,5-c][l,5]naphthyridine involves separating by centrifugation.
  • a precipitate there are many other ways to separate the solid (i.e., a precipitate) from the mixture, such as decanting and filtering.
  • the present invention provides a method for preparing 2-methyl-l-(2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine.
  • the method includes providing 2-methyl-l-(2-methylpropyl)-5-oxido-lH-imidazo[4,5- e][l,5]naphthyridine in a carrier that includes a lower alcohol; combining the 2-methyl-l- (2-methylpropyl)-5-oxido-lH-imidazo[4,5-c][l,5]naphthyridine in the carrier with an ammonia- or ammonium-containing reagent and an arylsulfonyl halide to form a mixture; allowing the components of the mixture to react for a period of time sufficient to form 2- methyl-l-(2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridin
  • the step of providing 2-methyl-l-(2-methylpropyl)-5-oxido- lH-imidazo[4,5-c][l,5]naphthyridine in a carrier that includes a lower alcohol occurs at a temperature of at least 20 0 C. In some embodiments, this temperature is no greater than 30 0 C.
  • the ammonia- or ammonium- containing reagent is preferably added prior to the arylsulfonyl halide.
  • the ammonia- or ammonium-containing reagent includes ammonium hydroxide in water.
  • the ammonia- or ammonium-containing reagent includes less than ten equivalents of ammonium hydroxide.
  • combining the 2-methyl- l-(2-methyrpropyl)-5-oxido- IH- imidazo[4,5-c] [1 ,5]naphthyridine in the carrier with an ammonia- or ammonium- containing reagent is carried out at a temperature of at least 20 0 C. In some embodiments, this temperature is no greater than 30 0 C.
  • the ammonia- or ammonium-containing reagent is added to the 2-methyl- 1 -(2-methylpropyl)-5-oxido- 1 H-imidazo [4,5 -c] [ 1 ,5]naphthyridine. This addition preferably occurs relatively quickly with continuous agitation.
  • agitating a mixture such as stirring, shaking, and sonicating.
  • the arylsulfonyl halide is benzenesulfonyl chloride orp- toluenesulfonyl chloride.
  • combining an arylsulfonyl halide (typically after the ammonia- or ammonium- containing compound is added) is carried out at a temperature of at least 20 0 C. In some embodiments, this temperature is no greater than 30 0 C.
  • allowing the components of the mixture to react for a period of time sufficient to form 2-methyl-l-(2-methylpropyl)-lH-imidazo[4,5- c] [1 ,5]naphthyridin-4-amine is carried out at a temperature of at least 20 0 C. In some embodiments, this temperature is no greater than 30 0 C.
  • the period of time sufficient to form 2-methyl- 1 -(2- methylpropyl)-lH " -imidazo[4,5-c][l,5]naphthyridin-4-amine is at least 45 minutes. In some embodiments, this period of time is no greater than 75 minutes.
  • the method further includes a step of combining the mixture with an aqueous base. Typically, sufficient aqueous base is added to adjust the mixture to a pH of greater than 8, and preferably greater than 10.
  • the aqueous base is aqueous sodium hydroxide, although other alkali metal hydroxides (e.g., potassium hydroxide) or other aqueous bases (e.g., sodium carbonate, potassium carbonate) could be used if desired.
  • the method further includes a step of cooling the mixture to a temperature of no greater than 15 0 C. In some embodiments, this temperature is at least 15 0 C.
  • this method can further include separating at least a portion of the resultant 2-methyl-l-(2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine from at least a portion of the mixture, and, if desired, further include washing and at least partially drying the resultant 2-methyl-l-(2-methylpropyl)-lH-imidazo[4,5- c] [1 ,5]naphthyridin-4-amine.
  • a precipitate from the mixture, such as filtering, decanting, and centrifugation. After separation, the precipitate may optionally be washed with water to remove impurities. Furthermore, one skilled in the art will appreciate that there are many ways to at least partially dry the precipitate. This includes, for example, using elevated temperatures, desiccation, reduced pressure, using a dry (e.g., nitrogen) atmosphere, and the like. In one embodiment, at least partially drying the precipitate occurs at a temperature range of 25 0 C to 60 0 C under at least a partial vacuum.
  • Isobutylamine (9.4 kg, 12.8 L, 130 mol) was added to a stirred suspension of the material from Part A (20.55 kg) in tetrahydrofuran (67 L) over a period of 77 minutes while maintaining a reaction temperature of 20 0 C to 27 0 C.
  • the addition of isobutylamine was followed by a rinse with tetrahydrofuran (5 L).
  • the reaction was stirred for 190 minutes at a temperature of 20 0 C to 24 0 C, and then water (288 L) was added over a period of about one hour while maintaining the reaction temperature at 21.4 0 C to 23.8 0 C.
  • the resulting mixture was stirred at 20 0 C to 24 0 C for 75 minutes and then filtered.
  • the isolated solid was washed with water (4 x 25 L) that had also been used to rinse the reaction vessel, pulled dry under vacuum, and further dried under vacuum for 60 hours at a temperature of 45 0 C to 55 0 C to provide 13.7 kg of N 4 -(2-methylpropyl)-3- nitro[l ,5]naphthyridin-4-amine.
  • the resulting mixtures were cooled to a temperature of approximately 10 0 C over a period of 60 minutes.
  • a solid formed in each mixture and was isolated by filtration, and each solid was washed with demineralized water (2 x 2 L and 1 x 1 L) until the pH of the filtrate equaled the pH of demineralized water.
  • Isobutylamine (784 g, 10.7 mol) was added to a suspension of the material from Part A in tetrahydrofuran (6 L) over a period of 45 minutes while maintaining a reaction temperature of 17 0 C to 27 0 C. When the addition was 75% complete, yellow needles formed in the solution. After the addition was complete, the reaction was stirred for 30 minutes at a temperature of 21.5 0 C to 22.5 0 C and then added with stirring to two portions of demineralized water (12 L each). The resulting mixtures were stirred for 30 minutes. The solid formed in each mixture was isolated by filtration, and each solid was washed with demineralized water (2 x 2 L) until the pH of the filtrate equaled the pH of demineralized water. The solids were then dried overnight on the filter funnels to provide 1.225 kg of N 4 -(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine as a yellow solid.
  • a hydro genation vessel was charged with ⁇ -(2-methylpropyl)-3- nitro[l,5]naphthyridin-4-amine (7.50 kg, 30.5 mol) and toluene (125.0 kg).
  • reaction mixture was then placed under hydrogen pressure (2.4 x 10 5 Pa, 2.4 bars) for six hours while stirring and maintaining the temperature at 22 0 C.
  • the reaction mixture was then filtered, and the filter cake was washed with toluene (30.0 kg).
  • the filtrate was concentrated under reduced pressure (1 x 10 4 Pa, 0.1 bar) at approximately 50 0 C to provide a solution of iV 4 -(2-methylpropyl)[l,5]naphthyridine-3,4-diamine in toluene (75 L, approximately 10 mL/g).
  • Part C Peracetic acid (7.15 kg of 40% w/w) was added over a period of 60 minutes to the
  • aqueous ammonium hydroxide (four equivalents) was quickly added with continuous stirring to a suspension of 2-methyl-l-(2- methylpropyl)-l/f-imidazo[4,5-c][l,5]naphthyridin-5-oxide in methanol (6 mL/g) while maintaining the reaction temperature at 20 0 C to 24 0 C. Methanol was used to rinse the addition vessel and added to the reaction. The reaction was stirred until all material was dissolved. With continuous stirring, benzenesulfonyl chloride (2 equivalents) was added over a period of 15 to 45 minutes while maintaining the reaction temperature at 20 0 C to 30 0 C. Methanol was used to rinse the addition vessel and added to the reaction.
  • reaction was stirred for 45 to 75 minutes at 20 0 C to 24 0 C.
  • Aqueous sodium hydroxide (3 equivalents of 10% w/w) was added to the reaction mixture over a period of 15 to 45 minutes while maintaining the reaction temperature between 20 0 C and 25 0 C.
  • Water (10 L) used to rinse the addition vessel, was added to the reaction mixture.
  • the resulting mixture was cooled to 10 0 C and stirred for 2 to 24 hours. A precipitate was present and was isolated by filtration and washed with deionized water until the filtrate was pH 7.
  • reaction was stirred for one hour at 22 0 C.
  • a solution of aqueous sodium hydroxide (15.0 kg of 25% w/w) and water (34.0 kg) was added to the reaction mixture over a period of 30 minutes at 22 0 C to adjust the mixture to p ⁇ 13.
  • the resulting mixture was cooled to 11 0 C and stirred at that temperature for three hours and then separated by centrifugation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2005/047375 2004-12-30 2005-12-28 Process for preparing 2-methyl-1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine Ceased WO2006074046A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US11/794,584 US8436176B2 (en) 2004-12-30 2005-12-18 Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
BRPI0519797-0A BRPI0519797A (pt) 2004-12-30 2005-12-28 método para a preparação de 2-metil-1-(2-metilpropil)-1h-imidazo [4, 5-c] [1, 5] naftiridin-4-amina, método para a obtenção de n4-(2-metilpropil)-3-nitro [1, 5] naftiridin-4-amina e método para a obtenção de 2-metil-1-(2-metilpropil)-5-oxido-1h-imidazo [4, 5-c] [1, 5] naftiridina
AT05855868T ATE510838T1 (de) 2004-12-30 2005-12-28 Verfahren zur herstellung von 2-methyl-1-(2- methylpropyl)-1h-imidazoä4,5-cüä1,5ünaphthyridi - 4-amin
PL05855868T PL1833827T3 (pl) 2004-12-30 2005-12-28 Sposób wytwarzania 2-metylo-1-(2-metylopropylo)-1H-imidazo[4,5-c][1,5]naftyrydyno-4-aminy
AU2005322844A AU2005322844A1 (en) 2004-12-30 2005-12-28 Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
EP05855868A EP1833827B9 (en) 2004-12-30 2005-12-28 Process for preparing 2-methyl-1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine
CA002592957A CA2592957A1 (en) 2004-12-30 2005-12-28 Process for preparing 2-methyl-1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine
MX2007008131A MX2007008131A (es) 2004-12-30 2005-12-28 Proceso para preparar 2-metil-1-(2-metilpropil)-1h-imidazo[4,5-c][ 1,5]naftiridin-4-amina.
DK05855868.5T DK1833827T3 (da) 2004-12-30 2005-12-28 Fremgangsmåde til fremstilling af 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amin
JP2007549617A JP2008526758A (ja) 2004-12-30 2005-12-28 ２−メチル−１−（２−メチルプロピル）−１ｈ−イミダゾ［４，５−ｃ］［１，５］ナフチリジン−４−アミンの製造方法
IL184310A IL184310A (en) 2004-12-30 2007-06-28 Process for preparing 2-methyl-1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine
NO20076651A NO339859B1 (no) 2004-12-30 2007-12-21 Fremgangsmåte for fremstilling av 2-metyl-l-(2-metylpropyl)-1H-imidazo[4,5-c][1,5]naftyridin-4-amin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64112904P 2004-12-30 2004-12-30
US60/641,129 2004-12-30
US70867905P 2005-08-16 2005-08-16
US60/708,679 2005-08-16

Publications (2)

Publication Number Publication Date
WO2006074046A2 true WO2006074046A2 (en) 2006-07-13
WO2006074046A3 WO2006074046A3 (en) 2007-08-16

Family

ID=36615477

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/047375 Ceased WO2006074046A2 (en) 2004-12-30 2005-12-28 Process for preparing 2-methyl-1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine
PCT/US2005/047068 Ceased WO2006071862A2 (en) 2004-12-30 2005-12-28 Polymorphs of 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2005/047068 Ceased WO2006071862A2 (en) 2004-12-30 2005-12-28 Polymorphs of 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate

Country Status (16)

Country Link
US (2) US8436176B2 (https=)
EP (2) EP1833833A2 (https=)
JP (2) JP2008526758A (https=)
AT (1) ATE510838T1 (https=)
AU (1) AU2005322844A1 (https=)
BR (1) BRPI0519797A (https=)
CA (2) CA2592957A1 (https=)
CR (1) CR9217A (https=)
DK (1) DK1833827T3 (https=)
IL (1) IL184310A (https=)
MX (1) MX2007008131A (https=)
NO (1) NO339859B1 (https=)
PL (1) PL1833827T3 (https=)
PT (1) PT1833827E (https=)
RU (1) RU2388760C2 (https=)
WO (2) WO2006074046A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655672B2 (en) 2004-12-17 2010-02-02 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8124096B2 (en) 2006-07-31 2012-02-28 3M Innovative Properties Company Immune response modifier compositions and methods
US10005772B2 (en) 2006-12-22 2018-06-26 3M Innovative Properties Company Immune response modifier compositions and methods

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
AU2004268625B2 (en) 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
KR20060120069A (ko) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
EP1687308B1 (en) * 2003-11-17 2019-06-12 Merck & Cie Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
WO2005118586A1 (en) * 2004-06-02 2005-12-15 Sandoz Ag Meropenem intermediate in crystalline form
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
EP1789042B1 (en) 2004-09-02 2012-05-02 3M Innovative Properties Company 1-alkoxy 1h-imidazo ring systems and methods
JP5543068B2 (ja) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
EP1831221B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Substituted chiral fused 1,2 imidazo 4,5-c ring compounds
US8378102B2 (en) 2005-02-09 2013-02-19 3M Innovative Properties Company Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
EP1845988A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
JP2008531567A (ja) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン化合物および方法
EP1851224A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
AU2006216686A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
EA200800782A1 (ru) 2005-09-09 2008-08-29 Коли Фармасьютикал Груп, Инк. ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ
BRPI0616040A2 (pt) * 2005-09-21 2011-06-07 Nycomed Gmbh cloridrato de sulfonilpirról como inibidor de histona desacetilases
EP2404911A1 (en) * 2005-10-31 2012-01-11 Janssen Pharmaceutica NV Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
KR20080083270A (ko) 2005-11-04 2008-09-17 콜레이 파마시티컬 그룹, 인코포레이티드 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
CA2667345C (en) * 2006-10-27 2016-03-22 Signal Pharmaceuticals, Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
US9242980B2 (en) 2010-08-17 2016-01-26 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
JP2013536859A (ja) * 2010-09-01 2013-09-26 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストの非吸湿性塩
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
BR112013031039B1 (pt) 2011-06-03 2020-04-28 3M Innovative Properties Co compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
EP2760859A1 (en) * 2011-09-30 2014-08-06 Sunshine Lake Pharma Co., Ltd Crystalline forms of azilsartan and preparation and uses thereof
WO2013165898A2 (en) * 2012-05-01 2013-11-07 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting resolvases
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
KR20170139074A (ko) 2015-04-24 2017-12-18 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
WO2019123178A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3764681A (en) 1970-07-08 1973-10-09 Lilly Co Eli Certain tetrazolo-(1,5-a) quinoline compounds as fungus control agents
US3917624A (en) 1972-09-27 1975-11-04 Pfizer Process for producing 2-amino-nicotinonitrile intermediates
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
DK0553202T3 (da) 1990-10-05 1995-07-03 Minnesota Mining & Mfg Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
JPH09500128A (ja) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー イミダゾ〔４，５−ｃ〕ピリジン−４−アミン
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
JPH09208584A (ja) 1996-01-29 1997-08-12 Terumo Corp アミド誘導体、およびそれを含有する医薬製剤、および合成中間体
JPH09255926A (ja) 1996-03-26 1997-09-30 Diatex Co Ltd 粘着テープ
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
IL129319A0 (en) 1996-10-25 2000-02-17 Minnesota Mining & Mfg Immune response modifier compounds for treatment of TH2 mediated and related diseases
PT839810E (pt) 1996-11-04 2003-01-31 Bayer Cropscience Sa 1-poliarilpirazois como pesticidas
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
US6069149A (en) 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
JPH11222432A (ja) 1998-02-03 1999-08-17 Terumo Corp インターフェロンを誘起するアミド誘導体を含有する外用剤
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6518280B2 (en) * 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
HU229441B1 (en) 1999-01-08 2013-12-30 3M Innovative Properties Co Formulations and methods for treating mucosal associated conditions with an immune response modifier
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (ja) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US20020110840A1 (en) 2000-12-08 2002-08-15 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US20020107262A1 (en) * 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US7226928B2 (en) 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
JP2005501550A (ja) 2001-08-30 2005-01-20 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法
US7132438B2 (en) * 2001-10-09 2006-11-07 Amgen Inc. Benzimidazole derivatives
US20030139364A1 (en) 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
EP1455700A4 (en) 2001-11-16 2007-02-14 3M Innovative Properties Co METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS
ES2312659T3 (es) 2001-11-29 2009-03-01 3M Innovative Properties Company Formulaciones farmaceuticas que comprenden un modificador de la respuesta inmune.
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
HUE025145T2 (en) 2002-02-22 2016-01-28 Meda Ab A method for reducing and treating immunosuppression induced by ultraviolet B radiation
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2003101949A2 (en) 2002-05-29 2003-12-11 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
JP2005538057A (ja) 2002-06-07 2005-12-15 スリーエム イノベイティブ プロパティズ カンパニー エーテル置換イミダゾピリジン
AU2003259226A1 (en) * 2002-07-23 2004-02-09 Biogal Gyogyszergyar Rt Preparation of 1h-imidazo(4,5-c)quinolin-4-amines via1h-imidazo (4,5-c)quinolin-4-phthalimide intermediates
PT1539752E (pt) * 2002-07-26 2007-05-31 Teva Gyogyszergyar Zartkoeruen Preparação de 1h-imidazo [4,5-c] quinolina-4-aminas via novos intermediários imidazo [4,5-c] quinolina-4-ciano e 1h-imidazo [4,5-c] quinolina-4-carboxamida
DK1545597T3 (da) 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
JP2006503068A (ja) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー １ｈ−イミダゾダイマー
AU2003287316A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004053057A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
CA2510375A1 (en) 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
EP1599726A4 (en) 2003-02-27 2009-07-22 3M Innovative Properties Co SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
JP2006519866A (ja) 2003-03-04 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー Ｕｖ誘発性の表皮の新形成の予防的治療
JP2006519877A (ja) 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー １−アミノ１ｈ−イミダゾキノリン
KR20050109562A (ko) 2003-03-13 2005-11-21 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피부의 질을 개선시키는 방법
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
WO2004080293A2 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
US20040191833A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
EP1615665A4 (en) 2003-04-10 2010-10-06 3M Innovative Properties Co DISTRIBUTION OF THE IMMUNE RESPONSE MODIFYING LINKS
WO2004096144A2 (en) 2003-04-28 2004-11-11 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
JP2007504232A (ja) 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
EP1668010A2 (en) * 2003-10-01 2006-06-14 Taro Pharmaceuticals U.S.A., Inc. Method of preparing 4-amino-1h -imidazo(4,5- c )quinolines and acid addition salts thereof
ITMI20032121A1 (it) * 2003-11-04 2005-05-05 Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm Procedimento per la preparazione di imiquimod e suoi intermedi
EP1685129A4 (en) * 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
WO2006084073A2 (en) * 2005-02-04 2006-08-10 Takeda Pharmaceutical Company Limited Aqueous gel formulations containing 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655672B2 (en) 2004-12-17 2010-02-02 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8557838B2 (en) 2004-12-17 2013-10-15 Medicis Pharmaceutical Corporation Immune response modifier formulations containing oleic acid and methods
US8124096B2 (en) 2006-07-31 2012-02-28 3M Innovative Properties Company Immune response modifier compositions and methods
US10005772B2 (en) 2006-12-22 2018-06-26 3M Innovative Properties Company Immune response modifier compositions and methods
US10144735B2 (en) 2006-12-22 2018-12-04 3M Innovative Properties Company Immune response modifier compositions and methods

Also Published As

Publication number Publication date
CA2592898A1 (en) 2006-07-06
JP2008526758A (ja) 2008-07-24
EP1833827B1 (en) 2011-05-25
ATE510838T1 (de) 2011-06-15
RU2388760C2 (ru) 2010-05-10
WO2006071862A2 (en) 2006-07-06
PT1833827E (pt) 2011-08-23
CR9217A (es) 2008-08-26
WO2006071862A3 (en) 2007-07-05
BRPI0519797A (pt) 2008-08-05
IL184310A (en) 2011-12-29
NO339859B1 (no) 2017-02-06
NO20076651L (no) 2007-12-21
PL1833827T3 (pl) 2011-10-31
DK1833827T3 (da) 2011-09-05
MX2007008131A (es) 2008-04-29
WO2006074046A3 (en) 2007-08-16
US20080306266A1 (en) 2008-12-11
AU2005322844A1 (en) 2006-07-13
JP2008535777A (ja) 2008-09-04
EP1833827B9 (en) 2012-01-04
IL184310A0 (en) 2007-10-31
US20090124652A1 (en) 2009-05-14
EP1833827A2 (en) 2007-09-19
US8436176B2 (en) 2013-05-07
EP1833833A2 (en) 2007-09-19
CA2592957A1 (en) 2006-07-13
EP1833827A4 (en) 2009-11-11
RU2007129092A (ru) 2009-02-10

Similar Documents

Publication Publication Date Title
US8436176B2 (en) Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
EP1765348B1 (en) Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
AU2004312508A1 (en) Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
JP2006513212A (ja) アリール／ヘタリール置換されたイミダゾキノリン
WO2006026760A2 (en) 1-amino imidazo-containing compounds and methods
WO2005048933A2 (en) Oxime substituted imidazo ring compounds
CN101255164A (zh) 稠合的二氢吡喃类化合物及其用途
EP2328900B1 (en) PROCESS FOR MAKING MORPHINAN-6 alpha-OLS
ZA200407766B (en) Novel alkoxypyridine-derivatives
NO323980B1 (no) Krystallinsk dihydrat B eller E olanzapin, fremgangsmate for fremstilling av Form II olanzapin samt preparat
HU229102B1 (en) 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
WO2006110893A2 (en) Preparation of tadalafil intermediates
FI110777B (fi) Menetelmä 7-[7-(S)-amino-5-atsaspiro[2.4]heptan-5-yyli]-8-kloori-6-fluori-1-[(1R,2S)-2-fluorisyklopropyyli]-4-okso-1,4-dihydrokinoliini-3-karboksyylihapon 3/2-hydraatin saamiseksi selektiivisesti
US20070100146A1 (en) Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
Buhr et al. Synthesis of a tetracyclic 2′-deoxyadenosine analog
JP4498923B2 (ja) イミダゾ（１，２−ａ）ピリジン−３−アセトアミド類の調製方法
ES2366652T3 (es) Procedimiento para la preparación de 2-metil-1-(2-metilpropil)-1h-imidazo(4,5-c)(1,5)naftíridin-4-amina.
MX2007009707A (es) Proceso para sintetizar tadalafil.
WO1995032199A1 (en) Process for preparing benzopyran compounds
EP0853622A1 (en) PROCESS FOR PREPARING 1-ARYL-4-OXOPYRROLO 3,2-c]QUINOLINE DERIVATIVES
WO2001072748A9 (en) Imidazopyridin-8-ones
EP2627655B1 (en) FUSED 3-OXO-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AS GABAA MODULATORS
EP0230016B1 (en) 6H-Isoxazolo[3,4-d]pyrazolo[3,4-b]pyridines, a process for their preparation and their use as medicaments
ZA200305364B (en) Method for purifying 20(S)-camptothecin.
WO2006053870A1 (en) A process for the preparation of n-demethylolanzapine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580048852.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 184310

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/008131

Country of ref document: MX

Ref document number: 2007549617

Country of ref document: JP

Ref document number: 2005322844

Country of ref document: AU

Ref document number: CR2007-009217

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2592957

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005855868

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005322844

Country of ref document: AU

Date of ref document: 20051228

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007129092

Country of ref document: RU

Ref document number: A20070962

Country of ref document: BY

WWE Wipo information: entry into national phase

Ref document number: 11794584

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0519797

Country of ref document: BR